Literature DB >> 17433227

[New routes of administration: epidermal, transcutaneous mucosal ways of vaccination].

François Denis1, Sophie Alain, Marie-Cécile Ploy.   

Abstract

A successful vaccine triggers the interaction of various cells of the immune system as does a regular immune response. It is thus necessary to introduce the vaccine antigens into an anatomic site where they will contact immune cells. The route of administration is thus critical for the outcome of vaccination. Intramuscular or subcutaneous injections are the most popular. Antigens injected intramuscularly can form persistent precipitates that are dissolved and re-absorbed relatively slowly. If injecting antigens is a quick, easy and reproducible way to vaccination, it requires trained personnel. Alternatives exist, through non-invasive formulations which allow administration by the patient or a third party with no particular expertise. The skin, especially its epidermal layer, is an accessible and competent immune environment and an attractive target for vaccine delivery, through transcutaneous delivery or immunostimulant patches. Mucosal immunization is another strategy: its major rationale is that organisms invade the body via mucosal surfaces. Therefore, local protection at mucosal surface as well as systemic defense is beneficial. Various formulations of mucosal vaccines have been developed, such as the Sabin oral polio vaccine (OPV), rotavirus vaccines, cold-adapted influenza vaccines or vaccine against typhoid fever. Thus we are entering in an era where mucosal and transcutaneous immunisation will play an important role in disease management. However, it has not been so easy to obtain regulatory approval for mucosal or transcutaneous formulations and needle-based vaccines continue to dominate the market.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17433227     DOI: 10.1051/medsci/2007234379

Source DB:  PubMed          Journal:  Med Sci (Paris)        ISSN: 0767-0974            Impact factor:   0.818


  2 in total

1.  A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study.

Authors:  Svetomir N Markovic; Vera J Suman; Wendy K Nevala; Louis Geeraerts; Edward T Creagan; Lori A Erickson; Kendrith M Rowland; Roscoe F Morton; William L Horvath; Mark R Pittelkow
Journal:  Am J Clin Oncol       Date:  2008-12       Impact factor: 2.339

2.  Oat beta-glucan as a dietary supplement for dogs.

Authors:  Lívia Geraldi Ferreira; Mariangela Endrighi; Karen Guttenkunst Lisenko; Maiara Rodrigues Duarte de Oliveira; Mateus Resende Damasceno; Jelieny Aparecida Claudino; Pamella Godinho Gutierres; Ana Paula Peconick; Flávia Maria de Oliveira Borges Saad; Márcio Gilberto Zangeronimo
Journal:  PLoS One       Date:  2018-07-31       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.